Prodinger Peter Michael, Burgkart Rainer, Kreutzer Kilian, Liska Franz, Pilge Hakan, Schmitt Andreas, Knödler Martina, Holzapfel Boris Michael, Hapfelmeier Alexander, Tischer Thomas, Bissinger Oliver
Klinik und Poliklinik für Orthopädie und Sportorthopädie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Straße 22, D-81675, München, Germany.
Klinik und Poliklinik für Mund-, Kiefer- und Gesichtschirurgie, Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Germany.
PLoS One. 2016 Jul 25;11(7):e0159669. doi: 10.1371/journal.pone.0159669. eCollection 2016.
Low molecular weight heparin (LMWH) is routinely used to prevent thromboembolism in orthopaedic surgery, especially in the treatment of fractures or after joint-replacement. Impairment of fracture-healing due to increased bone-desorption, delayed remodelling and lower calcification caused by direct osteoclast stimulation is a well-known side effect of unfractioned heparin. However, the effect of LMWH is unclear and controversial. Recent studies strongly suggest impairment of bone-healing in-vitro and in animal models, characterized by a significant decrease in volume and quality of new-formed callus. Since October 2008, Rivaroxaban (Xarelto) is available for prophylactic use in elective knee- and hip-arthroplasty. Recently, some evidence has been found indicating an in vitro dose independent reduction of osteoblast function after Rivaroxaban treatment. In this study, the possible influence of Rivaroxaban and Enoxaparin on bone-healing in vivo was studied using a standardized, closed rodent fracture-model. 70 male Wistar-rats were randomized to Rivaroxaban, Enoxaparin or control groups. After pinning the right femur, a closed, transverse fracture was produced. 21 days later, the animals were sacrificed and both femora harvested. Analysis was done by biomechanical testing (three-point bending) and micro CT. Both investigated substances showed histomorphometric alterations of the newly formed callus assessed by micro CT analysis. In detail the bone (callus) volume was enhanced (sign. for Rivaroxaban) and the density reduced. The bone mineral content was enhanced accordingly (sign. for Rivaroxaban). Trabecular thickness was reduced (sign. for Rivaroxaban). Furthermore, both drugs showed significant enlarged bone (callus) surface and degree of anisotropy. In contrast, the biomechanical properties of the treated bones were equal to controls. To summarize, the morphological alterations of the fracture-callus did not result in functionally relevant deficits.
低分子量肝素(LMWH)常用于预防骨科手术中的血栓栓塞,尤其是在骨折治疗或关节置换术后。普通肝素因直接刺激破骨细胞导致骨吸收增加、重塑延迟和钙化降低而损害骨折愈合,这是一种众所周知的副作用。然而,低分子量肝素的作用尚不清楚且存在争议。最近的研究强烈表明,在体外和动物模型中低分子量肝素会损害骨愈合,其特征是新形成的骨痂体积和质量显著下降。自2008年10月起,利伐沙班(拜瑞妥)可用于择期膝关节和髋关节置换术的预防用药。最近,有证据表明利伐沙班治疗后体外成骨细胞功能呈剂量依赖性降低。在本研究中,使用标准化的封闭啮齿动物骨折模型研究了利伐沙班和依诺肝素对体内骨愈合的可能影响。70只雄性Wistar大鼠被随机分为利伐沙班组、依诺肝素组或对照组。固定右侧股骨后造成闭合性横形骨折。21天后,处死动物并取出双侧股骨。通过生物力学测试(三点弯曲)和显微CT进行分析。通过显微CT分析评估,两种研究药物均显示新形成骨痂的组织形态学改变。具体而言,骨(骨痂)体积增加(利伐沙班有统计学意义),密度降低。骨矿物质含量相应增加(利伐沙班有统计学意义)。小梁厚度降低(利伐沙班有统计学意义)。此外,两种药物均显示骨(骨痂)表面显著增大和各向异性程度增加。相比之下,治疗后骨骼的生物力学性能与对照组相当。总之,骨折骨痂的形态学改变并未导致功能上的相关缺陷。